Esperion Therapeutics, Inc. (ESPR)

USD 2.16

(-12.2%)

Market Cap (In USD)

425.59 Million

Revenue (In USD)

116.33 Million

Net Income (In USD)

-209.24 Million

Avg. Volume

5.48 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.58-3.94
PE
-
EPS
-
Beta Value
0.954
ISIN
US29664W1053
CUSIP
29664W105
CIK
1434868
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sheldon L. Koenig
Employee Count
-
Website
https://www.esperion.com
Ipo Date
2013-06-26
Details
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.